Disc Medicine, Inc.

Equities

IRON

US2546041011

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-19 pm EDT 5-day change 1st Jan Change
28.69 USD -4.43% Intraday chart for Disc Medicine, Inc. -9.86% -50.33%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Stifel Raises Price Target on Disc Medicine to $73 From $71, Keeps Buy Rating MT
Leerink Partners Cuts Price Target on Disc Medicine to $65 From $77, Keeps Outperform Rating MT
Lifesci Capital Cuts Price Target on Disc Medicine to $48 From $82, Keeps Outperform Rating MT
BMO Capital Cuts Disc Medicine's Price Target to $50 From $80, Maintains Outperform Rating MT
Stifel Adjusts Price Target on Disc Medicine to $71 From $104, Keeps Buy Rating MT
Morgan Stanley Cuts Price Target on Disc Medicine to $40 From $75, Says Bitopertin Trial's Missed Secondary Endpoint Increases Uncertainty on Regulatory Path; Equalweight Kept MT
North American Morning Briefing : Stocks Seen -2- DJ
Top Midday Decliners MT
Disc Medicine Trial of Light Sensitivity Treatment Achieves Primary Goal, But Misses Secondary Endpoint; Wedbush Cuts Price Target -- Shares Plunge MT
Raymond James Downgrades Disc Medicine to Outperform From Strong Buy, Cuts Price Target to $40 From $75 MT
Disc Medicine, Inc. Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Porphyria CI
Wedbush Raises Disc Medicine Price Target to $84 From $79, Maintains Outperform Rating MT
Disc Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Stifel Adjusts Price Target on Disc Medicine to $104 From $76, Maintains Buy Rating MT
Disc Medicine Names Pamela Stephenson as Chief Commercial Officer MT
Disc Medicine, Inc. Appoints Pamela Stephenson as Chief Commercial Officer CI
Disc Medicine Says FDA Grants Fast Track Designation for Investigational Treatment of Chronic Kidney Disease, Anemia MT
Disc Medicine Inc Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease CI
Disc Medicine Says Potential Blood Disease Treatment Gets FDA Orphan Drug Designation MT
Disc Medicine Gets Orphan Drug Designation for Blood-Disorder Treatment DJ
Disc Medicine, Inc. Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera CI
Disc Medicine, Inc. Announces Promotion of Jonathan Yu to Chief Operating Officer CI
Disc Medicine, Inc. Announces CFO Changes CI
Disc Medicine Insider Sold Shares Worth $6,934,125, According to a Recent SEC Filing MT
Disc Medicine Insider Sold Shares Worth $1,280,000, According to a Recent SEC Filing MT
Chart Disc Medicine, Inc.
More charts
Disc Medicine, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
28.69 USD
Average target price
57.11 USD
Spread / Average Target
+99.06%
Consensus
  1. Stock Market
  2. Equities
  3. IRON Stock
  4. News Disc Medicine, Inc.
  5. Disc Medicine Says FDA Grants Fast Track Designation for Investigational Treatment of Chronic Kidney Disease, Anemia